The Technical Analyst
Bavarian Nordic A/S [BVNRY]
Exchange: OTC Sector: Healthcare Industry: Biotechnology
Bavarian Nordic A/S Price, Forecast, Insider, Ratings, Fundamentals & Signals
3.33% $7.45
America/New_York / 3 mai 2024 @ 15:59
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 741.42 mill |
| EPS: | 0.920 |
| P/E: | 8.10 |
| Earnings Date: | May 08, 2024 |
| SharesOutstanding: | 233.75 mill |
| Avg Daily Volume: | 0.0050 mill |
| RATING 2024-05-03 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Buy | |
| DE: | Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.28x |
| Company: PE 8.10 | sector: PE 29.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.06x |
| Company: PE 8.10 | industry: PE 136.10 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 7.26 - 7.65 ( +/- 2.62%) |
| ATR Model: 14 days |
Forecast:
16:00 - $7.45
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $7.45 (3.33% ) |
| Volume | 0.0038 mill |
| Avg. Vol. | 0.0050 mill |
| % of Avg. Vol | 75.90 % |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For BVNRY
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
BVNRY
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN (freeze-dried) that has completed Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase II clinical trial for the treatment of SARS-CoV-2; and TAEK-VAC, which is in Phase I/II clinical trial for treatment of advanced HER2 and brachyury-expressing cancers. It has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. The company operates in the United States, Belgium, Germany, the Netherlands, Sweden, Switzerland, Austria, the United Kingdom, Japan, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
Latest Press Releases
2024-04-29 15:30:00 - Press Release
Bavarian Nordic Receives 65 Meur Contract To Supply Smallpox Vaccines For Eu Strategic Reserve
Copenhagen, denmark, april 29, 2024 – bavarian nordic a/s (omx: bava) today announced the award of a contract valued at eur 65 million to supply its mva-bn® smallpox vaccine to the strategic reserve within the european union (eu) in 2025. this third, and larger order follows two previous orders, received in 2023 and delivered in 2024, for smallpox vaccines to resceu stockpiles across europe and will help to expand the eu's capability to respond to future biological threats and emergencies by enabling rapid deployment of medical countermeasures to its member states.
2024-04-29 09:03:00 - Press Release
Bavarian Nordic Initiates Rolling Submission Of Biologics License Application With Fda For Its Chikungunya Vaccine Candidate
Copenhagen, denmark, april 29, 2024 – bavarian nordic a/s (omx: bava) today announced that it has initiated the rolling submission process with the u.s. food and drug administration (fda) for a biologics license application (bla) for the licensure of its chikv vlp vaccine candidate for immunization against chikungunya virus infection in individuals 12 years of age and older.
2024-04-22 12:00:00 - Press Release
Report Of Transactions Of Shares And Related Securities Of Bavarian Nordic By Persons Holding Managerial Responsibilities And/or Persons/companies Closely Associated With Such
Copenhagen, denmark, april 22, 2024 – bavarian nordic a/s (omx: bava) has today received information about the following transactions of the company's shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such.
2024-04-16 12:20:00 - Press Release
Resolutions Of The Annual General Meeting 2024 Of Bavarian Nordic A/s
Copenhagen, denmark, april 16, 2024 – bavarian nordic a/s (omx: bava) today held the annual general meeting with the following results:
2024-03-13 08:29:00 - Press Release
Bavarian Nordic Receives Approval Of Smallpox And Mpox Vaccine In Switzerland
Copenhagen, denmark, march 13, 2024 – bavarian nordic a/s (omx: bava) announced today that the swiss agency for therapeutic products, swissmedic, has approved jynneos® (mva-bn) for active immunization against disease caused by smallpox, mpox and vaccinia viruses in adults 18 years of age and older.
Latest News
2023-10-25 14:52:46 - Reuters
US CDC panel recommends Bavarian Nordic's vaccine for adults at risk of mpox
Bavarian Nordic said on Wednesday the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) has voted in favor of recommending the routine use of Jynneos vaccine for adults at risk of mpox.
2023-08-23 13:42:08 - Seeking Alpha
Bavarian Nordic A/S (BVNKF) Q2 2023 Earnings Call Transcript
Bavarian Nordic A/S (OTCPK:BVNKF) Q2 2023 Earnings Conference Call August 23, 2023 8:00 AM ET Company Participants Rolf Sass Sorensen - Vice President Investor Relations Paul Chaplin - President and Chief Executive Officer Jean-Christophe May - Executive Vice President, Chief Commercial Officer Henrik Juuel - Executive Vice President, Chief Financial Officer Conference Call Participants Thomas Bowers - Danske Bank Peter Verdult - Citigroup Boris Peaker - TD Cowen Gil Blum - Needham and Company Operator Good day, and thank you for standing by. Welcome to Bavarian Nordic's Half-Year Report Conference Call.
2023-07-22 13:22:39 - Reuters
Bavarian Nordic to discontinue RSV vaccine programme
Denmark-based Bavarian Nordic said on Saturday it was discontinuing its respiratory syncytial virus (RSV) vaccine programme as its Phase 3 clinical trial did not meet all the primary goals of preventing lower respiratory tract disease from RSV.
2023-05-18 13:12:10 - Reuters
People at high risk to mpox should get 2 doses of Bavarian Nordic vaccine, US CDC says
The U.S. Centers for Disease Control and Prevention is urging people at high risk of mpox to get two doses of Bavarian Nordic's Jynneos vaccine, based on new evidence from a U.S. study showing that two doses were more effective at preventing infection than one, officials said on Thursday.
2023-05-14 14:12:09 - Seeking Alpha
Bavarian Nordic A/S (BVNKF) Q1 2023 Earnings Call Transcript
Call Start: 08:00 January 1, 0000 8:50 AM ET Bavarian Nordic A/S (OTCPK:BVNKF) Q1 2023 Earnings Conference Call May 9, 2023 08:00 ET Company Participants Rolf Sorensen - Investor Relations Paul Chaplin - President & Chief Executive Officer Henrik Juuel - Executive Vice President & Chief Financial Officer Conference Call Participants Suzanne van Voorthuizen - VLK Gil Blum - Neeham & Company Thomas Bowers - Danske Bank Rolf Sorensen Welcome to everyone this evening. My name is Rolf Sorensen, VP, Investor Relations.
2023-04-25 12:25:46 - CNBC
Mpox outbreak was wake-up call for smallpox preparation, vaccine maker Bavarian Nordic says
Bavarian Nordic plans to sharply scale up production of its Jynneos vaccine to prepare for a smallpox emergency, CEO Paul Chaplin said.
2022-11-12 15:30:06 - Seeking Alpha
Bavarian Nordic A/S (BVNKF) Q3 2022 Earnings Call Transcript
Bavarian Nordic A/S (OTCPK:BVNKF) Q3 2022 Results Conference Call November 9, 2022 8:00 AM ET Company Participants Rolf Sorensen - Investor Relations Henrik Juuel - Executive Vice President, CFO Paul Chaplin - President and Chief Executive Officer Conference Call Participants Thomas Bowers - Danske Bank Gil Blum - Needham & Company Peter Verdult - Citigroup Boris Peaker - Cowen Sten Westerberg - Analysguiden Rolf Sorensen Yes. Thank you, operator, and good afternoon to some and good morning to the rest of you.
2022-09-20 03:36:00 - Market Watch
Bavarian Nordic shares jump after reaching smallpox, monkeypox vaccine deal extension
Shares of BAVA, +10.04% jumped 11% as the drugmaker said it signed a contract amendment with Public Health Canada that's valued at up to $434 million over ten years. Under the new contract amendment, the majority of the confirmed order for Imvamune will be delivered in 2023, Bavarian Nordic said.
2022-09-11 08:41:38 - Seeking Alpha
Bavarian Nordic A/S Could Post A Strong Comeback
Bearish sentiment weighed heavily on the biotech industry and Bavarian Nordic A/S. There is reason for optimism given the current opportunities offered by Monkeypox, Ebola and Covid-19.
2022-08-24 12:57:04 - Seeking Alpha
Bavarian Nordic A/S (BVNKF) CEO Paul Chaplin on Q2 2022 Results - Earnings Call Transcript
Bavarian Nordic A/S (OTCPK:BVNKF) Q2 2022 Earnings Conference Call August 24, 2022 8:00 AM ET Company Participants Rolf Sass – Investor Relations Paul Chaplin – President and Chief Executive Officer Henrik Juuel – Executive Vice President Conference Call Participants Thomas Bowers – Danske Bank Gil Blum – Needham and Company Peter Verdult – Citi Boris Pecker – Cowen Michael Novod – Nordea Operator Good day and thank you for standing by. Welcome to Bavarian Nordic Half Year Report Second Quarter for the six months period ended 30 of June 2022 Conference Call.